# Efficacy on Volume Reduction and Tolerance of Progressiv' Medical Compressive Therapy (MCT) V0322 BC in Patients With Chronic Venous Oedema

> **NCT01402921** · PHASE3 · COMPLETED · sponsor: **Pierre Fabre Medicament** · enrollment: 92 (actual)

## Conditions studied

- Chronic Venous Insufficiency (CVI)

## Interventions

- **DEVICE:** V0322 BC

## Key facts

- **NCT ID:** NCT01402921
- **Lead sponsor:** Pierre Fabre Medicament
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2012-01
- **Final completion:** 2012-03
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2016-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01402921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01402921, "Efficacy on Volume Reduction and Tolerance of Progressiv' Medical Compressive Therapy (MCT) V0322 BC in Patients With Chronic Venous Oedema". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01402921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*